An evaluation of the combination effect of zoledronate and chemotherapeutic agents in canine osteosarcoma cells

An evaluation of the combination effect of zoledronate and chemotherapeutic agents in canine osteosarcoma cells

IntroductionOsteosarcoma (OSA) is an aggressive form of bone cancer in both dogs and humans. The treatment options for metastatic (stage III) OSA are currently limited and the prognosis is poor. Zoledronate, a second generation amino-bisphosphonate, is commonly used for palliation of cancer induced...

Full description

Bibliographic Details
Main Authors: Yoshimi Iwaki, Stephanie E. S. Lindley, Noelle Bergman, Bruce F. Smith, Satyanarayana R. Pondugula
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-02-01
Series:Frontiers in Veterinary Science
Subjects:
dogs
osteosarcoma
chemotherapy
zoledronate
combination effect
Online Access:https://www.frontiersin.org/articles/10.3389/fvets.2024.1327377/full

Internet

https://www.frontiersin.org/articles/10.3389/fvets.2024.1327377/full

Similar Items